51 results
Page 2 of 3
8-K
EX-10.1
8vto6lyli32
26 Apr 22
Departure of Directors or Certain Officers
6:51am
8-K
EX-2.1
cr85 5ygt
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
424B5
q992jz845j
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-10.2
5ti5r2g4aoca91 rm
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-2.1
1yo3hfr3y11 nx3b
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
424B5
iojsovww
31 Dec 19
Prospectus supplement for primary offering
4:28pm
8-K
EX-10.2
4ukwz
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-10.1
808xxc
2 Oct 18
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
6:58am